 we report on our third quarter 2019 financial results and discuss our plans for commercialization of cytisinicline. 
 we also provide an update on the status of our ongoing clinical development program and plans for the upcoming phase three trials.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in 